Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalmefene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalmefene SCHEMBL18457569 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12646154 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18827079 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL14124638 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12233286 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL13267538 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL3114702 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18104559 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL19500879 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL35230 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147920-B1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-31 | — | — | EP | claimed |
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | claimed |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | claimed |
| EP-2137189-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT LLC (US) | 2015-05-06 | — | — | EP | claimed |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | VTESSE LLC | 2015-04-09 | — | — | US | claimed |
| EP-2441766-B1 | Nalmefene hydrochloride dihydrate | LUNDBECK & CO AS H (DK) | 2014-06-25 | — | — | EP | claimed |
| WO-2012166891-A2 | MU-OPIOID RECEPTOR BINDING COMPOUNDS | ALGYNOMICS INC. (US) | 2012-12-06 | — | — | WO | claimed |
| EP-2300479-B1 | NALMEFENE HYDROCHLORIDE DIHYDRATE | LUNDBECK & CO AS H (DK) | 2012-02-22 | — | — | EP | claimed |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2010-02-11 | — | — | US | claimed |
| EP-2147920-A2 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | Mallinckrodt Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | claimed |
| WO-1997047293-A1 | USE OF PREPARATIONS CONTAINING OPIATE ANTAGONISTS AND AGONISTS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF MIGRAINES | VIVA DIAGNOSTIKA DIAGNOSTISCHE PRODUKTE GMBH (DE) | 1997-12-18 | — | — | WO | claimed |
| US-20240197719-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | AEGIS THERAPEUTICS, LLC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240109907-A1 | PROCESS FOR CRYSTALLIZING NALMEFENE HYDROCHLORIDE | RHODES TECHNOLOGIES (US) | 2024-04-04 | — | — | US | disclosed |
| US-4478840-A | ANOREXIGENIC AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-23 | — | — | US | disclosed |
| US-4477457-A | Method for inducing anorexia using nalmetrene | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | TTN, PML, EMD | OPRD1 164/4885OPRM1 45/4885OPRK1 245/4885 |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRD1 406/4885OPRM1 60/4885OPRK1 527/4885 |
| US-20240197719-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | OPRK1, OPRM1, OGFR | OPRD1 5/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | RAN, RANBP1, NCLN | OPRD1 406/4885OPRM1 60/4885OPRK1 527/4885 |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRD1 406/4885OPRM1 60/4885OPRK1 527/4885 |
| US-20240109907-A1 | PROCESS FOR CRYSTALLIZING NALMEFENE HYDROCHLORIDE | OPRM1, NXF1, MME | OPRD1 14/4885OPRM1 1/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.